Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow Yield on January 14, 2025: 2.28%

Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow Yield is 2.28% on January 14, 2025, a -0.35% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Jiangsu Hengrui Medicine Co., Ltd. 52-week high Free Cash Flow Yield is 2.65% on February 02, 2024, which is 16.22% above the current Free Cash Flow Yield.
Jiangsu Hengrui Medicine Co., Ltd. 52-week low Free Cash Flow Yield is 1.71% on October 08, 2024, which is -24.81% below the current Free Cash Flow Yield.
Jiangsu Hengrui Medicine Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is 2.18%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years